Tuberculosis multidrogorresistente


PDF
XML
HTML
EPUB

Palabras clave

Tuberculosis
Infección
Farmacorresistencia Microbiana
Quimioterapia
Agentes Antituberculosos

Cómo citar

Urrego-Díaz, J. (2020). Tuberculosis multidrogorresistente. Revista Salud Bosque, 10(1). https://doi.org/10.18270/rsb.v10i1.2834

Resumen

La tuberculosis (TB) es la enfermedad bacteriana infecciosa que más muertes causa en el mundo, panorama que puede empeorar debido a la drogorresistencia. La tuberculosis multidrogoresistente (TB-MDR), es decir la que presenta resistencia simultánea a isoniazida y rifampicina (principales fármacos antituberculosos), tiene una relevancia particular: de los 10 millones de personas que desarrollan TB anualmente, 458.000 presentan TB-MDR con un pronóstico mucho peor que el de los infectados por cepas sensibles. En el presente artículo se exploran los principales aspectos de la TB-MDR, haciendo énfasis en su tratamiento.

https://doi.org/10.18270/rsb.v10i1.2834
PDF
XML
HTML
EPUB

Referencias

Murray PR, Rosenthal KS, Pfaller MA. Mycobacterium. En: Microbiología médica. 6ta ed. Barcelona: Elsevier Espa- ña; 2009.

Kumar V, Abbas AK, Fausto N, Aster JC. Micobacterias. En: Robbins y Cotran: Patología estructural y funcional. 8va ed. Barcelona: Elsevier España; 2010.

World Health Organization (WHO). Global tuberculosis report 2019. Geneva: WHO; 2019.

Raviglione MC. Tuberculosis. En: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editores. Ha- rrison: Principios de medicina interna. 18va ed. New York: McGraw-Hill; 2012.

Colombia. Instituto Nacional de Salud (INS). Informe de evento: Tuberculosis, Colombia, 2017. Bogotá, D.C.: INS; 2018.

Houben RM, Dodd PJ. The Global Burden of Latent Tuber- culosis Infection: A Re-estimation Using Mathematical Mo- delling. PLoS Med. 2016;13(10):e1002152. DOI: 10.1371/ journal.pmed.1002152.

Organización Panamericana de la Salud (OPS). Tubercu- losis en las Américas 2018. Washington, D.C.: OPS; 2018.

Colombia. Instituto Nacional de Salud (INS). Boletín Epi- demiológico Semanal. Semana epidemiológica 38. Bogotá D.C.: INS; 2018.

Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tu- berculosis. Lancet. 2010;375(9728):1830-43. DOI: 10.1016/ S0140-6736(10)60410-2.

Daley CL, Caminero JA. Management of Multidrug- Resistant Tuberculosis. Semin Respir Crit Care Med. 2018;39(3):310-24. DOI: 10.1055/s-0038-1661383.

Colombia. Ministerio de Salud y Protección Social (MinSalud). Circular externa 55 de 2016 (diciembre 20): Actualización DE los lineamientos para el manejo progra- mático de tuberculosis en niños, casos farmacoresistentes y aspectos de la programación de sintomáticos respirato- rios. Bogota D.C.: MinSalud; 2016.

Centers for Disease Control and Prevention (CDC). Core Curriculum on Tuberculosis: What the Clinician Should Know. 6ta ed. CDC; 2013.

Colombia. Ministerio de Salud y Protección Social, Institu- to Nacional de Salud. Lineamientos para el manejo progra- mático de pacientes con tuberculosis farmacorresistente. Bogotá D.C.: MinSalud; 2013.

Garzón MC, Angée DY, Llerena C, Orjuela DL, Victoria JE. Vigilancia de la resistencia del Mycobacterium tuberculo- sis a los fármacos antituberculosos, Colombia 2004-2005. Biomédica. 2008:28(3):319-26. DOI: 10.7705/biomedica. v28i3.71.

Mak A, Thomas A, Del Granado M, Zaleskis R, Mouza- farova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized re- gimens. Am J Respir Crit Care Med. 2008;178(3):306-12. DOI: 10.1164/rccm.200802-240OC.

Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med. 2008;149(2):123-34. DOI: 10.7326/0003-4819-149-2- 200807150-00008.

World Health Organization (WHO). Global tuberculosis report 2017. Geneva: WHO; 2017.

Colombia. Instituto Nacional de Salud (INS). Informe de actividades realizadas por la Red Nacional de Laborato- rios para la vigilancia de la resistencia de Mycobacterium tuberculosis a los fármacos Antituberculosos, Colombia 2013. Bogotá D.C.: INS; 2014.

Colombia. Instituto Nacional de Salud (INS). Protocolo de vigilancia en salud pública: Tuberculosis farmacoresisten- te. Bogotá, D.C.: INS; 2017.

World Health Organization (WHO). Treatment of tubercu- losis: guidelines for national programmes. Geneva: WHO; 2003. WHO.

World Health Organization (WHO). Global tuberculosis report 2016. Geneva: WHO; 2016.

Centers for Disease Control and Prevention (CDC). Labora- tory User Guide for U.S. Public Health Laboratories: Mole- cular Detection of Drug Resistance (MDDR) in Mycobac- terium tuberculosis Complex by DNA Sequencing (Version 2.0), June 2012. Atlanta: CDC; 2012 [citado 2019 sep 14]. Disponible en: https://www.cdc.gov/tb/topic/laboratory/ mddrusersguide.pdf.

Telenti A. Genetics and pulmonary medicine. 5. Genetics of drug resistant tuberculosis. Thorax. 1998;53(9):793-7. DOI: 10.1136/thx.53.9.793.

Fontalvo-Rivera D, Gómez-Camargo D. Genes del Myco- bacterium tuberculosis involucrados en la patogenicidad y resistencia a antibióticos durante la tuberculosis pulmonar y extrapulmonar. Medicas UIS. 2015;28(1):39-51.

Sacchettini JC, Blanchard JS. The structure and function of the isoniazid target in M. tuberculosis. Res Microbiol. 1996;147(1-2):36-43. DOI: 10.1016/0923-2508(96)80201-4.

Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase- peroxidase gene and isoniazid resistance of Mycobacte- rium tuberculosis. Nature. 1992;358(6387):591-3. DOI: 10.1038/358591a0.

Heym B, Alzari PM, Honoré N, Cole ST. Missense muta- tions in the catalase-peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis. Mol Microbiol. 1995;15(2):235-45. DOI: 10.1111/j.1365- 2958.1995.tb02238.x.

Cockerill FR, Uhl JR, Temesgen Z, Zhang Y, Stockman L, Roberts GD, et al. Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. J Infect Dis. 1995;171(1):240-5. DOI: 10.1093/infdis/171.1.240.

Brennan PJ, Nikaido H. The envelope of mycobacteria. An- nu Rev Biochem. 1995;64:29-63. DOI: 10.1146/annurev. bi.64.070195.000333.

Rozwarski DA, Grant GA, Barton DH, Jacobs WR, Sa- cchettini JC. Modification of the NADH of the isonia- zid target (InhA) from Mycobacterium tuberculosis. Science. 1998;279(5347):98-102. DOI: 10.1126/scien- ce.279.5347.98.

Bloom BR. Tuberculosis: Pathogenesis, Protection, and Control. Washington DC: ASM Press; 1994.

Miller LP, Crawford JT, Shinnick TM. The rpoB gene of Mycobacterium tuberculosis. Antimicrob Agents Che- mother. 1994;38(4):805-11. DOI: 10.1128/aac.38.4.805.

Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341(8846):647- 50. DOI: 10.1016/0140-6736(93)90417-f.

Cole ST. Rifamycin resistance in mycobacteria. Res Microbiol. 1996;147(1-2):48-52. DOI: 10.1016/0923- 2508(96)80203-8.

World Health Organization (WHO). Consolidated guide- lines on drug-resistant tuberculosis treatment. Geneva: WHO; 2019.

World Health Organization (WHO). WHO Treatment Gui- delines for Drug-Resistant Tuberculosis: 2016 Update. Ge- neva: WHO; 2016.

Colombia. Ministerio de Salud y Protección Social. Linea- mientos técnicos y operativos del programa nacional de tuberculosis [documento en consulta interna]. Bogotá: MinSalud; 2019.

World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO; 2011.

World Health Organization (WHO). The Use of bedaqui- line in the Treatment of MultidrugResistant Tuberculosis: Interim Policy Guidance. Geneva: WHO; 2013.

World Health Organization (WHO). The Use of delamanid in the Treatment of MultidrugResistant Tuberculosis: Inte- rim Policy Guidance. Geneva: WHO; 2014.

World Health Organization (WHO). The use of delamanid in the treatment of multidrug-resistant tuberculosis in chil- dren and adolescents: interim policy guidance. Geneva: WHO; 2016.

World Health Organization (WHO). Guidelines for the treatment of drug-susceptible tuberculosis and patient ca- re: 2017 update. Geneva: WHO; 2017.

World Health Organization (WHO). WHO treatment gui- delines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tubercu- losis. Geneva: WHO; 2018.

World Health Organization. WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis: 2018 update. Geneva: WHO; 2018.

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Socie- ty/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95. DOI: 10.1093/cid/ciw376.

Curry International Tuberculosis Center. Drug-Resistant Tu- berculosis: A Survival Guide for Clinicians. 3ra ed. Wash- ington D.C.; CITC; 2016.

World Health Organization (WHO). Rapid communica- tion: key changes to treatment of multidrug- and rifampi- cin-resistant tuberculosis (TB-MDR/RR). Geneva: WHO; 2019 [citado 2019 sep 20]. Disponible en: https://www. who.int/tb/publications/2019/WHO_RapidCommunica- tionMDRTB2019.pdf?ua=1.

Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A Trial of a Shorter Regimen for Rifampin- Resistant Tuberculosis. N Engl J Med. 2019;380(13):1201- 13. DOI: 10.1056/NEJMoa1811867.

Deltyba (delamanid). Amsterdam: European Medicines Agency; 2018 [citado 2019 sep 27]. Disponible en: https:// www.ema.europa.eu/en/medicines/human/EPAR/deltyba.

Sirturo (bedaquiline). Amsterdam: European Medicines Agency; 2014. [citado 2019 sep 27]. Disponible en: https:// www.ema.europa.eu/en/medicines/human/EPAR/sirturo.

World Health Organization (WHO). WHO best-practice statement on the off-label use of bedaquiline and delama- nid for the treatment of multidrug-resistant tuberculosis. Geneva: WHO; 2017 [citado 2019 sep 27]. Disponible en: http://apps.who.int/iris/bitstream/10665/258941/1/WHO- HTM-TB-2017.20-eng.pdf.

Tuberculosis multidrogorresistente

José Augusto Urrego-Díaz

Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, et al. Short, highly effective, and inexpensive stan- dardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684-92. DOI: 10.1164/ rccm.201001-0077OC.

Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for TB-MDR patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517-24. DOI: 10.5588/ijtld.14.0535.

Piubello A, Harouna SH, Souleymane MB, Boukary I, Mo- rou S, Daouda M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18(10):1188- 94. DOI: 10.5588/ijtld.13.0075.

Ahmad-Khan F, Salim MAH, du Cros P, Casas EC, Kha- mraev A, Sikhondze W, et al. Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate da- ta meta-analyses. Eur Respir J. 2017;50(1):1700061. DOI: 10.1183/13993003.00061-2017..

World Health Organization (WHO). Position Statement on the Continued Use of the Shorter TB-MDR Regimen fo- llowing an Expedited Review of the STREAM Stage 1 Preli- minary Results. Geneva: WHO; 2018.

MoodleyR,GodecTR,TeamST.Short-coursetreatmentfor multidrug-resistant tuberculosis: the STREAM trials. Eur Res- pir Rev. 2016;25(139):29-35. : 10.1183/16000617.0080-2015.

Caminero JA, Caylac JA, García-García JM, García-Pérez FJ, Palacios JJ, Ruiz-Manzano J. Diagnóstico y tratamien- to de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017;53(9):501-9. DOI: 10.1016/j.ar- bres.2017.02.006.

World Health Organization (WHO). Public call for indi- vidual patient data on treatment of rifampicin and multi- drugresistant (TB-MDR/RR) tuberculosis. Geneve: WHO; 2018 [citado 2019 sep 22]. Disponible en: http://www. who.int/tb/features_archive/public_call_treatment_RR_ MDR_TB/en/.

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant pulmonary tuberculo- sis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300. DOI: 10.1371/journal.pmed.1001300.

Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, An- derson LF, Baghaei P, et al. Treatment correlates of suc- cessful outcomes in pulmonary multidrug-resistant tu- berculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821-34. DOI: 10.1016/S0140- 6736(18)31644-1.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e1002591. DOI: 10.1371/journal.pmed.1002591.

von Groote-Bidlingmaier F, Patientia R, Sanchez E, Ba- lanag V, Ticona E, Segura P, et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-con- trolled, parallel group phase 3 trial. Lancet Respir Med. 2019;7(3):249-59. DOI: 10.1016/S2213-2600(18)30426-0.

Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, et al. Improved treatment outcomes with bedaquiline when substituted for second-line injectable agents in multidrug re- sistant tuberculosis: a retrospective cohort study. Clin Infect Dis. 2018 ;68(9):1522-1529. DOI: 10.1093/cid/ciy727.

Borisov SE, Dheda K, Enwerem M, Romero-Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safe- ty of bedaquiline-containing regimens in the treatment of MDR- and XTB-DR: a multicentre study. Eur Respir J. 2017;49(5):1700387. DOI: 10.1183/13993003.00387-2017.

Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retros- pective cohort study. Lancet Respir Med. 2018;6(9):699- 706. DOI: 10.1016/S2213-2600(18)30235-2.

Diacon AH, Pym A, Grobusch MP, de los Rios JM, Go- tuzzo E, Vasilyeva I, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723-32. DOI: 10.1056/NEJMoa1313865.

Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-405. DOI: 10.1056/NEJMoa0808427.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Che- mother. 2012;56(6):3271-6. DOI: 10.1128/AAC.06126-11.

Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug- resistant pulmonary tuberculosis. Cochrane Database Syst Rev. 2019;3(3):CD012836. DOI: 10.1002/14651858. CD012836.pub2.

Koh WJ, Lee SH, Kang YA, Lee CH, Choi JC, Lee JH, et al. Comparison of levofloxacin versus moxifloxacin for mul- tidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858-64. DOI: 10.1164/rccm.201303-0604OC.

Creative Commons License
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial 4.0.

Descargas

La descarga de datos todavía no está disponible.